Literature DB >> 11679977

Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression.

P Boya1, E Larrea, I Sola, P L Majano, C Jiménez, M P Civeira, J Prieto.   

Abstract

The mechanisms of liver damage in chronic hepatitis C virus (HCV) infection are poorly understood. The transcription factor, nuclear factor-kappa B (NF-kappa B), regulates the expression of genes involved in apoptosis, inflammation, and antiviral response. It plays a protective role in several forms of liver damage. In this study, we analyzed NF-kappa B by gel mobility shift assay and immunohistochemistry in liver biopsies from HCV-infected patients, and we have determined the hepatic levels of the components of the NF-kappa B system by semiquantitative polymerase chain reaction (PCR). We found that NF-kappa B was activated in the liver of patients with chronic hepatitis C. Neither NF-kappa B activity nor the RNA levels of NF-kappa B subunits showed correlation with liver inflammatory activity, viral load, or HCV genotype. By contrast, hepatic mRNA values of RelA, the main element of active NF-kappa B, correlated inversely with apoptosis (r = -.68; P <.05) and with the rate of fibrosis progression (r = -.51; P <.04). In intermediate/rapid fibrosers, RelA mRNA levels were significantly decreased as compared with slow fibrosers (P <.003) and with normal livers (P <.03). In conclusion, we found that NF-kappa B is activated in chronic HCV-infected livers, and that the expression of RelA is inversely correlated with liver cell apoptosis and with the rate of fibrosis progression. Our data thus suggest that RelA expression may protect against liver fibrosis and hepatocellular damage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679977     DOI: 10.1053/jhep.2001.29002

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

Review 1.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

2.  NF-κB RelA Is Required for Hepatoprotection during Pneumonia and Sepsis.

Authors:  Yuri Kim; Eri Allen; Lillia A Baird; Elise M Symer; Filiz T Korkmaz; Elim Na; Christine V Odom; Matthew R Jones; Joseph P Mizgerd; Katrina E Traber; Lee J Quinton
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

Review 3.  NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma.

Authors:  Tom Luedde; Robert F Schwabe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

Review 4.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 5.  Hepatitis E and pregnancy: understanding the pathogenesis.

Authors:  Udayakumar Navaneethan; Mayar Al Mohajer; Mohamed T Shata
Journal:  Liver Int       Date:  2008-07-25       Impact factor: 5.828

6.  Selective suppression of NF-kBp65 in hepatitis virus-infected pregnant women manifesting severe liver damage and high mortality.

Authors:  Bhupesh K Prusty; Suresh Hedau; Ajay Singh; Premasis Kar; Bhudev C Das
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

Review 7.  Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways.

Authors:  Salvatore Papa; Concetta Bubici; Francesca Zazzeroni; Guido Franzoso
Journal:  Biol Chem       Date:  2009-10       Impact factor: 3.915

Review 8.  The interferon inducing pathways and the hepatitis C virus.

Authors:  Eliane F Meurs; Adrien Breiman
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

9.  Computational models of liver fibrosis progression for hepatitis C virus chronic infection.

Authors:  James Lara; F López-Labrador; Fernando González-Candelas; Marina Berenguer; Yury E Khudyakov
Journal:  BMC Bioinformatics       Date:  2014-07-14       Impact factor: 3.169

Review 10.  Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects.

Authors:  Ming Hong; Sha Li; Hor Yue Tan; Ning Wang; Sai-Wah Tsao; Yibin Feng
Journal:  Int J Mol Sci       Date:  2015-12-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.